GlassScriptPhysician profile
Yuji Umeda
NPI 1497998496
$2,069.06
in general payments reported to CMS, 2019-2025
15 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2021: $279 · 2022: $137 · 2023: $424 · 2024: $431 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $432.75 | 2019-2023 | Xiaflex |
| Depuy Synthes Sales INC. | $321.83 | 2021-2025 | Dynacord, Milagro, Truespan Orthocord |
| Endo USA, INC. | $281.60 | 2025 | Xiaflex |
| Stryker Corporation | $153.90 | 2024 | Variax, Conextions Tr Tendon Repair System-Implant Mechanism |
| Bone Support INC. | $147.36 | 2025 | Cerament G, Ceramentbone Void Filler |
| Medical Device Business Services, INC. | $141.48 | 2025 | Tfn-Advance |
| Skeletal Dynamics INC | $140.16 | 2024 | Ijs, Geminus, Implate |
| Checkpoint Surgical, INC | $137.39 | 2024 | Checkpoint Stimulators |
| Polynovo North America LLC | $131.42 | 2023 | |
| Medartis INC. | $49.18 | 2021 | |
| Dexcom, INC. | $34.57 | 2021 | |
| Grt US Holding, INC. | $32.77 | 2022 | |
| Averitas Pharma INC. | $29.58 | 2023 | Qutenza |
| Si-Bone, INC. | $19.30 | 2021 | |
| Pfizer INC. | $15.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuji Umeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.